Citius Oncology, Inc. (CTOR) Fair Value 2026

CTOR · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.9 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, Citius Oncology, Inc. (CTOR) trades at $0.69, approximately 1485% above CirclFi’s Bayesian DCF fair value of $0.04. QOC: 3.9/10. Value Trap Risk: 24/100 (SAFE). 10/13 models active.

Key Facts

Ticker
CTOR
Price
$0.69
Quality Score
3.9/10
Value Trap Risk
24/100
Models Active
10/13
Last Updated
Strength: First Chicago suggests +33.4% upside with 12% confidence
Risk: Below-average Quality Score of 3.9/10 signals weak fundamentals

Is Citius Oncology, Inc. (CTOR) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Citius Oncology, Inc. (CTOR) appears overvalued as of : the median of 10 independent fair value estimates is $0.20, 71.2% below the current price of $0.69. Estimates range from $0.04 to $0.92. CTOR scores 3.9/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Citius Oncology, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($0.69)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
 $0.04 -93.7%
CUCE Ensemble
Low Conviction
 $0.22 -68.2%
First Chicago
Low Conviction
 $0.92 +33.4%
ML-RIV
Medium Conviction
 $0.08 -88.8%

Unlock the Full Matrix

Access 6 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Citius Oncology, Inc. (CTOR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Citius Oncology, Inc.'s intrinsic value is estimated at a composite fair value of $0.40. Trading at $0.69, the stock is approaching fair value or slight overvaluation (implied return of -41.8%), as 6 of 10 models suggest limited further upside. The most optimistic model, First Chicago, places fair value at $0.92 (+33.4%), while Bayesian DCF — the most conservative — estimates $0.04 (-93.7%). This +127.1% gap reflects genuine analytical uncertainty about Citius Oncology, Inc.'s intrinsic worth.

What Do the Models Say About CTOR?

10 of 13 models are currently active for CTOR. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates CTOR's intrinsic value at $0.04, implying -93.7% downside from the current price. See which stocks rank higher →

How Does CTOR Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, CTOR ranks #343 by Quality of Company score. CirclFi's QOC score of 3.9/10 evaluates 32 fundamental signals. A score of 3.9 signals below-average fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

Citius Oncology, Inc.'s positioning within the Pharmaceutical Preparations segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is CTOR a Value Trap?

CirclFi's Value Trap algorithm assigns CTOR a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Citius Oncology, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Citius Oncology, Inc. earns a quality score of 3.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +127.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTOR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CTOR's 10 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Citius Oncology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Citius Oncology, Inc.

What is Citius Oncology, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Citius Oncology, Inc. (CTOR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.04. The Quality of Company score is 3.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTOR overvalued or undervalued right now?

At $0.69, 4 of 10 active models suggest CTOR may be undervalued, while 6 indicate potential overvaluation. The median of all 10 fair value estimates is $0.20, 71.2% below the current price of $0.69 — a consensus view that CTOR is overvalued. The assessment depends on which methodology best fits Citius Oncology, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 3.9 mean for CTOR?

Citius Oncology, Inc.'s QOC of 3.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CTOR?

CirclFi analyzes CTOR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is CTOR a value trap in 2026?

Citius Oncology, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Citius Oncology, Inc. (CTOR) has a median fair value of $0.20 — 71.2% below the current price of $0.69 — as of 2026-07-15.” Source: circlfi.com/stock/CTOR/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on CTOR.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access